Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development

A scar is proof you survived – a good thing. Uncontrolled scarring, called fibrosis, is a threat unto itself (think cirrhosis) or an impediment to clinical intervention (think macrophages, T-cells and cancer). Mechanisms that drive both involve the molecule, Gal-3, and an enzyme, LOXL2. The mission of Galecto is drugging these targets with small molecule, first-in-class inhibitors. Hear how Galecto’s CEO, Dr. Hans Schambye, made their mission his own.